Renovacor, Inc.

Chardan NexTech Acquisition 2 Corp. (Nasdaq: CHAQ), a blank-check company sponsored by Chardan Capital Markets, completed its initial public offering in 2021 with a focus on the healthcare and biotechnology sector. The SPAC pursued a business combination with Renovacor, Inc., a gene therapy company developing treatments for inherited cardiovascular diseases including dilated cardiomyopathy, a genetic condition causing heart failure. An 8-K disclosure was filed with the SEC on December 1, 2022, under accession number 0001193125-22-296600, reflecting a material corporate development tied to the transaction. Sign up on SpacDesk for the full filing history, deal timeline, and data analytics on CHAQ and hundreds of other SPACs.